Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 12/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30211617 | 1.00 | CHRM1 (0.49) | CHRM1KCNH2ALOX5CYP2C9SYK | |
| SCHEMBL26360372 | 0.91 | CHRM1 (0.43) | CHRM1KCNH2ALOX5CYP2C9SYK | |
| SCHEMBL30211606 | 0.90 | KCNH2 (0.43) | CHRM1KCNH2ALOX5CYP2C9PDE11A | |
| SCHEMBL23827790 | 0.90 | KCNH2 (0.43) | CHRM1KCNH2ALOX5CYP2C9PDE11A | |
| SCHEMBL30211584 | 0.89 | KCNH2 (0.44) | CHRM1KCNH2ALOX5CYP2C9 | |
| SCHEMBL23827760 | 0.89 | KCNH2 (0.44) | CHRM1KCNH2ALOX5CYP2C9 | |
| SCHEMBL23843691 | 0.86 | CHRM1 (0.42) | CHRM1KCNH2ALOX5CYP2C9SYK | |
| SCHEMBL30211669 | 0.86 | CHRM1 (0.42) | CHRM1KCNH2ALOX5CYP2C9SYK | |
| SCHEMBL30211626 | 0.84 | CHRM1 (0.51) | CHRM1KCNH2ALOX5CYP2C9CYP11B1 | |
| SCHEMBL23827746 | 0.84 | CHRM1 (0.51) | CHRM1KCNH2ALOX5CYP2C9CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303541-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF ACETYLCHOLINE RECEPTORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-09-28 | — | — | US | disclosed |
| US-20230303541-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF ACETYLCHOLINE RECEPTORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-09-28 | — | — | US | disclosed |
| US-11560372-B2 | Heterocyclic compounds useful as modulators of acetylcholine receptors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-01-24 | — | — | US | disclosed |
| US-11560372-B2 | Heterocyclic compounds useful as modulators of acetylcholine receptors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-01-24 | — | — | US | disclosed |
| US-20210292308-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF ACETYLCHOLINE RECEPTORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-09-23 | — | — | US | disclosed |
| US-20210292308-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF ACETYLCHOLINE RECEPTORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303541-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF ACETYLCHOLINE RECEPTORS | CHRM3, CHRNA1, CHRM5 | CHRM1 7/4885KCNH2 429/4885ALOX5 1501/4885 |
| US-20210292308-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF ACETYLCHOLINE RECEPTORS | CHRM3, CHRNA1, CHRM5 | CHRM1 9/4885KCNH2 436/4885ALOX5 1529/4885 |
| US-11560372-B2 | Heterocyclic compounds useful as modulators of acetylcholine receptors | CHRM3, CHRNA1, CHRM5 | CHRM1 9/4885KCNH2 436/4885ALOX5 1529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.